Experimental therapy could eliminate the need for insulin

Experimental therapy could eliminate the need for insulin
Experimental therapy could eliminate the need for insulin

Scientists have proposed a new therapy for type 2 diabetes. If therapy is found to be effective, it may help some people stop insulin treatment.

Scientists have proposed a new therapy to treat type 2 diabetes. A proof-of-concept study shows positive initial results. If therapy is effective, it may mean some people stop taking insulin treatment.

The study’s authors presented their findings at UEG Week Virtual 2020, a conference organized by United European Gastroenterology, a professional non-profit organization for digestive health professionals.

According to the National Institute for Diabetes and Digestive and Kidney Diseases, a person can have type 2 diabetes if their blood sugar is too high.
People get blood sugar, or blood sugar, mostly from the food they eat. Insulin helps cells access this glucose for use as energy. In a person with type 2 diabetes, either their body is not making enough insulin or their cells are not responding properly to insulin.

This then means that the glucose in their blood rises, which can lead to complications in diabetes like heart and kidney disease, visual disturbances, and loss of sensation in the limbs. The higher the blood sugar over time, the higher the risk of these complications.

According to the Centers for Disease Control and Prevention (CDC), about one in ten adults in the United States has diabetes, and 90–95% of these people have type 2 diabetes.

Doctors usually recommend lifestyle changes such as: B. A healthier diet to treat type 2 diabetes and medication to control a person’s blood pressure and sugar levels.

Insulin treatment may be needed if a person cannot keep their blood sugar at normal levels. This treatment can take the form of injections, pens, pumps, or inhalers. It stimulates the cells in a person’s body to take up more blood sugar.

However, people’s perception of the side effects of insulin treatment can be very high. As a result, doctors may be less likely to prescribe insulin, and if so, people may not take it regularly.

Consequently, therapies that can help avoid these perceived side effects can be helpful in ensuring that people are keeping up with their prescribed treatment and avoiding the risk of serious health problems.

In this context, the researchers behind the present study used a novel technique that scientists first used in humans in 2016. Based on these preliminary results, it looked promising.
The technique is known as Duodenal Mucosal Resurfacing (DMR). The duodenum is the first part of a person’s small intestine. In DMR, the lining of the duodenum is raised so that heated water can ablate the exposed area – a process that removes the cells in the target area.

The researchers who developed the DMR technique tried to reproduce the beneficial effects of bariatric surgery (gastric bypass) on blood sugar levels using a less invasive technique.

Studies of how bariatric surgery improves blood sugar control have found that in addition to the weight loss that results from bariatric surgery, there is a direct effect on the duodenum.

DMR can be performed on an outpatient basis and is minimally invasive. It is an endoscope catheter to gain access to the duodenum.

The direct effect of the small intestine on glucose control appears to be due to the presence of intraepithelial lymphocyte T cells. These are located between the intestinal cells that are involved in the absorption of nutrients from food.

Mice without these cells are protected from obesity and heart disease, even if they eat a high-fat diet.

These intraepithelial lymphocytes reduce the amount of an intestinal hormone called GLP-1. Therefore, in the current study, the researchers added regular doses of a GLP-1 agonist called liraglutide on day 14.

They did this to counteract the reduced amount of this essential lean, anti-diabetic hormone. Study participants were also given lifestyle advice to help them lower their blood sugar levels.

The study included 16 participants with type 2 diabetes who received insulin treatment. Of the participants who received DMR therapy with liraglutide, 12 (75%) were able to discontinue use of insulin and maintain blood sugar control after 6 months.

Study participants also saw a number of benefits for their metabolism.
The HbA1c levels of the participants who determine an individual’s glucose control had all fallen below 7.5%. After 12 months it fell further to 6.7%.

Those who responded to treatment saw their body mass index decrease by an average of 29.8 kilograms per square meter (kg / m).2) before the start of the study to 25.5 kg / m2 12 months after the study. The fat in the livers of the participants decreased from 8.1% to 4.6% after 6 months.

Even for those participants who still needed insulin, the amount required decreased from an average of 35 units per day to 17 units per day after 12 months.

According to Dr. Suzanne Meiring, researcher at the Amsterdam University Hospital in the Netherlands and co-leader of the study,

“A single endoscopic DMR ablation with GLP-1 drugs and lifestyle counseling can lead to discontinuation of insulin therapy in a subset of patients with type 2 diabetes while improving glycemic control and overall metabolic health.”

“Many patients with type 2 diabetes are very happy to be able to discontinue insulin therapy because insulin therapy is associated with weight gain and hypoglycemic events.”

It is important to note that this is a very small proof of concept study. The researchers presented it as a conference paper, which is why few details are publicly available.
The intervention combined two innovative treatments. There is no information on the side effects of either treatment (DMR and GLP-1 agonist). Although encouraging, larger studies are needed to confirm the results.

It is important that it is not yet clear how and why the therapy appears to be working.

Scientists believe it might work because the mucosal cells affected by DMR therapy experience changes in response to unhealthy diets that can promote insulin resistance.

“Based on the results of this study, a large international randomized controlled trial called Revita T2Di Pivotal will soon begin further investigating its effectiveness in larger numbers,” says Dr. Meiring.

These were the details of the news. Experimental therapy could eliminate the need for insulin for that day. We hope that we managed to give you all the details and information. To keep up with all of our news you can subscribe to the notification system or one of our various systems to receive everything that is new.

It’s also worth noting that the original news has been published and is available at de24.news. AlKhaleej Today’s editorial team has confirmed this and it has been changed and it may have been fully retransmitted or quoted and you can read it and follow this news from its main source.

These were the details of the news Experimental therapy could eliminate the need for insulin for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV The researchers observe a “worrying” decline in antibodies against corona recoverers
NEXT Preliminary results show China’s COVID-19 vaccine candidate is safe: The Lancet